Teage Ezard, the chef responsible for venues including Gingerboy and Ezard, was diagnosed with an incurable neurological ...
The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...
Clinical-stage biotech Alterity Therapeutics has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as it advances its lead drug candidate ATH434 toward a ...
Abstract: Real-time simulation (RTS) is indispensable for validating multiple grid-connected converter systems that form the backbone of renewable energy stations. In this article, an RTS model for ...
Abstract: Existing current signal-based open-circuit fault diagnosis methods necessitate real-time analysis of extensive historical current data for fault feature extraction, which leads to large ...
An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...
Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results